Shares of Seaport, a drugmaker that recently completed its initial public offering, rose 17% in early trading after the company raised $255 million in an upsized offering.
The IPO, which priced above the expected range, drew significant interest from institutional and retail investors alike.
Analysts noted that the increased capital will support Seaport's ongoing research and development efforts, particularly in its core therapeutic areas.
The stock's performance highlights the market's positive reception to the firm's business model and pipeline.
Analysts noted that the increased capital will support Seaport's ongoing research and development efforts, particularly in its core therapeutic areas.
The biopharmaceutical sector has seen a wave of new listings in recent months, with investors seeking exposure to high-growth companies.
Seaport's successful IPO adds to this trend, signaling continued confidence in the sector's long-term prospects.